Results 1 to 10 of about 896,426 (307)

Decreased Deposition of Beta-Amyloid 1-38 and Increased Deposition of Beta-Amyloid 1-42 in Brain Tissue of Presenilin-1 E280A Familial Alzheimer’s Disease Patients

Frontiers in Aging Neuroscience, 2020
Familial Alzheimer’s Disease (FAD) caused by Presenilin-1 (PS1) mutations is characterized by early onset, cognitive impairment, and dementia. Impaired gamma secretase function favors production of longer beta-amyloid species in PS1 FAD.
Felix Dinkel, Diana Trujillo-Rodriguez, Andres Villegas, Johannes Streffer, Marc Mercken, Francisco Lopera, Markus Glatzel, Diego Sepulveda-Falla   +7 more
doaj   +3 more sources

Plasma Beta-Amyloid and Metabolic Biomarkers: Age- and Sex-Stratified Analyses Suggest Limited Population-Level Associations [PDF]

Medicina
Background and Objectives: This study examined the relationships between plasma beta-amyloid levels and systemic inflammatory, thyroid, and lipid biomarkers using complementary analytical approaches in a cross-sectional cohort undergoing plasma OAβ and ...
Hyeokjun Yun, Bo Kyeung Jung, Jae Kyung Kim   +2 more
doaj   +2 more sources

Hippocampal Beta-Amyloid Accumulation In Aluminium Chloride and D-Galactose-Induced Rats: Establishing a Nontransgenic Alzheimer’s Model

Journal of Pharmacy and Bioallied Sciences
Background: Alzheimer’s disease (AD) is characterized by tau protein aggregation and beta-amyloid (Aβ) plaques leading to progressive cognitive decline.
Thirupathirao Vishnumukkala, Samaila M. Chiroma, Saravanan Jagadeesan, Prarthana K. Gopalakrishna, Sreenivasulu Sura, Nurul H. Mohd Nor, Mohamad A. Mohd Moklas   +6 more
doaj   +2 more sources

The Features of Beta-Amyloid Phosphorylation in Alzheimer's Disease. [PDF]

Acta Naturae
Accumulation of neurotoxic aggregates of beta-amyloid peptides (Aβ) is a hallmark of Alzheimer’s disease (AD) progression. Post-translational modifications (PTMs) increase Aβ aggregation and cytotoxicity, and the content of specific Aβ proteoforms is elevated in senile plaques of AD patients. The pathophysiological mechanisms of aggregate formation and
Strelnikova PA, Bugrova AE, Zakharova NV, Danichkina KV, Indeykina MI, Gavrish MS, Krut' VG, Babaev AA, Morozova AY, Kononikhin AS, Mitkevich VA, Makarov AA, Nikolaev EN.   +12 more
europepmc   +3 more sources

Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease

Neural Regeneration Research, 2022
Alzheimer’s disease is a neurodegenerative disease that accounts for most of the 50-million dementia cases worldwide in 2018. A large amount of evidence supports the amyloid cascade hypothesis, which states that amyloid-beta accumulation triggers tau ...
Alejandro R Roda, Gabriel Serra-Mir, Laia Montoliu-Gaya, Lidia Tiessler, Sandra Villegas   +4 more
doaj   +1 more source

Cognitive and brain cytokine profile of non-demented individuals with cerebral amyloid-beta deposition

Journal of Neuroinflammation, 2021
Background Brain inflammation has been increasingly associated with early amyloid accumulation in Alzheimer’s disease models; however, evidence of its occurrence in humans remains scarce.
Lisi Flores-Aguilar, M. Florencia Iulita, Chiara Orciani, Neil Tanna, Jingyun Yang, David A. Bennett, A. Claudio Cuello   +6 more
doaj   +1 more source

Beta-amyloid imaging with florbetaben [PDF]

Clinical and Translational Imaging, 2015
Florbetaben is a fluorine-18 (18F)-labeled stilbene derivative that was developed as a positron emission tomography (PET) tracer for routine clinical application to visualize β-amyloid plaques in the Alzheimer's disease (AD) brain. The tracer successfully completed a global multicenter phase 0-III development program and was, as a consequence, recently
Sabri, O, Seibyl, J, Rowe, C, Barthel, H
openaire   +3 more sources

Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model. [PDF]

PLoS ONE, 2010
beta-amyloid levels are elevated in Down syndrome (DS) patients throughout life and are believed to cause Alzheimer's disease (AD) in adult members of this population.
William J Netzer, Craig Powell, Yi Nong, Jacqueline Blundell, Lili Wong, Karen Duff, Marc Flajolet, Paul Greengard   +7 more
doaj   +1 more source

Beta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort

Molecular Brain, 2022
The accumulation of beta amyloid in the brain has a complex and poorly understood impact on the progression of Parkinson’s disease pathology and much controversy remains regarding its role, specifically in cognitive decline symptoms.
Alexander S. Mihaescu, Mikaeel Valli, Carme Uribe, Maria Diez-Cirarda, Mario Masellis, Ariel Graff-Guerrero, Antonio P. Strafella   +6 more
doaj   +1 more source

The Roles of the Amyloid Beta Monomers in Physiological and Pathological Conditions

Biomedicines, 2023
Amyloid beta peptide is an important biomarker in Alzheimer’s disease, with the amyloidogenic hypothesis as one of the central hypotheses trying to explain this type of dementia.
Thomas Gabriel Schreiner, Oliver Daniel Schreiner, Maricel Adam, Bogdan Ovidiu Popescu   +3 more
doaj   +1 more source